Contact
searchSearch
HMP Global

Hidradenitis Suppurativa

Featured Article

News
Comfort, Interest, and Therapy Choices Differ Between Hidradenitis Suppurativa Experts and Non-Experts in Complex Cases
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
Two Genetic Variants Implicated in Risk of Hidradenitis Suppurativa
11/22/2023
Jolynn Tumolo
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation...
11/22/2023
First Report Managed Care
Quiz
The Impact of HS Diagnosis on Comorbidity Burden
10/27/2023
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity...
10/27/2023
First Report Managed Care
News
Costs, Comorbidity Burden High in US Patients With Hidradenitis Suppurativa
09/20/2023
Jolynn Tumolo
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require...
09/20/2023
First Report Managed Care
News
HS: Targeted Therapies and Training May Improve Patient Quality of Life
08/31/2023
Danielle Sposato
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa...
08/31/2023
First Report Managed Care

Newsfeed

News
Comfort, Interest, and Therapy Choices Differ Between Hidradenitis Suppurativa Experts and Non-Experts in Complex Cases
12/20/2023
Lisa Kuhns, PhD, MD
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American guidelines for HS management were recently published in 2019 from both the United States and Canadian HS Foundations, barriers to HS expertise among dermatologists still exist,” wrote coauthors.
“Although North American...
12/20/2023
First Report Managed Care
News
Two Genetic Variants Implicated in Risk of Hidradenitis Suppurativa
11/22/2023
Jolynn Tumolo
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation analysis, researchers found that inflammatory bowel disease, psoriasis, and type 2 diabetes may share certain genetic factors with hidradenitis suppurativa. However, additional studies are needed to shed light on...
In a genetic correlation...
11/22/2023
First Report Managed Care
Quiz
The Impact of HS Diagnosis on Comorbidity Burden
10/27/2023
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity burden tends to decrease after HS diagnosis.
True or False: The comorbidity...
10/27/2023
First Report Managed Care
News
Costs, Comorbidity Burden High in US Patients With Hidradenitis Suppurativa
09/20/2023
Jolynn Tumolo
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require comprehensive care strategies involving a multidisciplinary team of physicians to improve health while reducing health care expenditures,” researchers advised.
“Patients with HS may require...
09/20/2023
First Report Managed Care
News
HS: Targeted Therapies and Training May Improve Patient Quality of Life
08/31/2023
Danielle Sposato
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa treatment involves pharmacological and surgical options, but systemic treatment is restricted, with only adalimumab, an anti-TNF-a antibody, approved.
Hidradenitis suppurativa...
08/31/2023
First Report Managed Care
Conference Coverage
Oral Premedication Could Improve Treatment for Patients with Multiple Sclerosis
07/09/2026
Rebecca Amrick
Research presented at the National Infusion Center Association (NICA) 2026 Annual Conference found that oral premedication for patients with multiple sclerosis (MS) was associated with fewer and less severe infusion-related reactions.
Research presented at the National Infusion Center Association (NICA) 2026 Annual Conference found that oral premedication for patients with multiple sclerosis (MS) was associated with fewer and less severe infusion-related reactions.
Research presented at the...
07/09/2026
First Report Managed Care
News
TKI Discontinuation Supports Long-Term Treatment-Free Remission in Chronic-Phase CML
07/08/2026
Grace Taylor, MS, MA
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies found that approximately half of patients with chronic-phase chronic myeloid leukemia (CML) remained in treatment-free remission for up to 36 months after discontinuing tyrosine kinase inhibitor (TKI) therapy,...
A meta-analysis of 16 studies...
07/08/2026
First Report Managed Care
News
Tirzepatide Demonstrates Improved Clinical Benefit and Lower Costs than Semaglutide in Adults With Obesity
07/08/2026
Rebecca Amrick
A simulation model demonstrated that tirzepatide had better clinical outcomes and less medical costs than semaglutide for patients with obesity or overweight, supporting prior research that highlighted tirzepatide as a viable treatment...
A simulation model demonstrated that tirzepatide had better clinical outcomes and less medical costs than semaglutide for patients with obesity or overweight, supporting prior research that highlighted tirzepatide as a viable treatment...
A simulation model demonstrated...
07/08/2026
First Report Managed Care
News
Electronic Interventions Could Reduce Reliance on Benzodiazepines
07/06/2026
Rebecca Amrick
Electronic interventions could allow patients taking benzodiazepines to actively manage their prescriptions and reduce drug reliance, which would improve self-management of care without excessive cost burdens.
Electronic interventions could allow patients taking benzodiazepines to actively manage their prescriptions and reduce drug reliance, which would improve self-management of care without excessive cost burdens.
Electronic interventions could...
07/06/2026
First Report Managed Care
News
Real-World Study Supports Omalizumab for Food Allergy Management
07/02/2026
Hannah Musick
Real-world data suggest that omalizumab enabled most patients with food allergy to successfully tolerate oral food challenges and introduce previously allergenic foods into their diets, with generally manageable allergic reactions during...
Real-world data suggest that omalizumab enabled most patients with food allergy to successfully tolerate oral food challenges and introduce previously allergenic foods into their diets, with generally manageable allergic reactions during...
Real-world data suggest that...
07/02/2026
First Report Managed Care
Behind the Bill
House Advances Bipartisan Legislation to Ease Quality Reporting Burden for Medicare ACOs
07/02/2026
Grace Taylor, MS, MA
The US House of Representatives (House) unanimously approved H.R. 5347, bipartisan legislation that would provide greater flexibility for Medicare Accountable Care Organizations (ACOs) transitioning to digital quality reporting.
The US House of Representatives (House) unanimously approved H.R. 5347, bipartisan legislation that would provide greater flexibility for Medicare Accountable Care Organizations (ACOs) transitioning to digital quality reporting.
The US House of Representatives...
07/02/2026
First Report Managed Care
Behind the Bill
Medicare Cost Cap Act Would Establish Out-of-Pocket Maximum in Traditional Medicare
06/26/2026
Grace Taylor, MS, MA
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would establish the first annual out-of-pocket spending limit in traditional Medicare, a change that could reshape beneficiary affordability and the competitive landscape across Medicare coverage options.
The Medicare Cost Cap Act would...
06/26/2026
First Report Managed Care
News
Omalizumab Associated With Reduced HCRU and Disease-Related Costs for Food Allergies and Asthma
06/25/2026
Rebecca Amrick
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in reducing health care resource utilization (HCRU) and associated care costs for patients with comorbid food allergies and asthma, according to a study published in the Journal of Allergy and Clinical Immunology:...
Omalizumab shows promise in...
06/25/2026
First Report Managed Care
News
Social Determinants of Health Negatively Impact Mortality Among Patients With ESKD
06/24/2026
Rebecca Amrick
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage kidney disease (ESKD) studies identified multiple health disparities across various domains, highlighting the connection between access barriers and ESKD mortality.
A systematic review of end-stage...
06/24/2026
First Report Managed Care
News
Outpatient Cilta-Cel Administration May Reduce Health Care Utilization in RRMM
06/23/2026
Rebecca Amrick
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care settings sufficient for administering ciltacabtagene autoleucel (cilta-cel) to patients with relapsed or refractory multiple myeloma (RRMM), suggesting that outpatient utilization could reduce the burden on...
A study found outpatient care...
06/23/2026
First Report Managed Care

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use